Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.

Beatrice Del Papa Stefano BaldoniErica DorilloFilomena De FalcoChiara RompiettiDebora CecchiniMaria Grazia CantelmiDaniele SorciniManuel NogarottoFrancesco Maria AdamoFederica MezzasomaEstevão Carlos Silva BarcelosElisa AlbiRoberta Iacucci OstiniAmbra Di TommasoAndrea MarraGuido MontanaroMaria Paola MartelliFranca FalzettiMauro Di IanniEmanuela RosatiPaolo Sportoletti

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

We demonstrated a strong clinical activity of ibrutinib in a real-life context. The ibrutinib clinical efficacy was associated with NOTCH1 activity downregulation that deepened over time. Our data point to NOTCH1 as a new molecular partner in BCR signaling with potential to further improve CLL-targeted treatments.

Keyphrases

chronic lymphocytic leukemia
cell proliferation
acute lymphoblastic leukemia
electronic health record
big data
tyrosine kinase
drug delivery
machine learning
single molecule
deep learning